Hsin Loke joins the Cell and Gene Therapy Catapult as Non-Executive Director
London, United Kingdom, 26 September 2024: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has appointed a new Non-Executive Director to its board, Dr Hsin Loke.
Dr Hsin Loke has over 25 years’ experience in the life science industry. Hsin is currently SVP, of Finance and Operations, at OMass Therapeutics, a small molecule drug discovery company that is focused on developing new therapies for immunology and orphan diseases. Previously, she held a variety of finance and operational leadership roles at GSK, including in its Rare Diseases Unit which developed and commercialised a portfolio of innovative medicines and gene therapies.
Hsin qualified as a Chartered Accountant with PwC, after completing her BA (Hons) in Biological Sciences and D.Phil. in genetics and immunology at Oxford University. She has also been a Trustee and Audit Committee member at BookTrust, the UK's largest reading charity for children.
Ian McCubbin, Chairman of the CGT Catapult said: “We are excited to welcome Hsin onto the board, bringing her exceptional experience in finance and operations and her passion for life sciences. The work of the CGT Catapult over the past 12 years has been a major factor in the growth of the advanced therapies industry in the UK and ensuring that patients have access to new, innovative treatments. We are continuing these efforts and Hsin will play a valuable role at the CGT Catapult, helping us to ensure the industry reaches its full potential and delivers health and economic benefits across the UK.”
Dr Hsin Loke, Non-Executive Director of the CGT Catapult says: “The CGT Catapult is uniquely positioned to accelerate the delivery of transformative new therapies to patients and position the UK competitively in this fast-moving field. I am delighted to be joining the CGT Catapult’s Board and look forward to contributing my experience working across the UK life science ecosystem to deliver our mission.”
